World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
40
Citations
9187
World Ranking
4923
National Ranking
2197

Overview

Paul M. Sondel is affiliated with the University of Wisconsin-Madison in the United States. Their research focuses primarily on fields related to Medicine, Biochemistry, Genetics and Molecular Biology, as well as Immunology and Microbiology.

The scientist's subfield expertise includes Oncology, Immunology, Neurology, Molecular Biology, and Radiology, Nuclear Medicine and Imaging. Their work covers several main topics that involve Neuroblastoma Research and Treatments, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cancer, Hypoxia, and Metabolism, and Monoclonal and Polyclonal Antibodies Research.

Sondel has published research extensively, with notable recent papers including:

  • Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade, 2021, Science Translational Medicine
  • Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032, 2021, Clinical Cancer Research
  • Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group, 2020, Journal of Clinical Oncology
  • Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment, 2022, Nature Communications
  • Immunotherapy of Neuroblastoma: Facts and Hopes, 2022, Clinical Cancer Research

Frequent collaborators in Sondel's work include Amy K. Erbe, Alexander L. Rakhmilevich, Zachary S. Morris, Arika S. Feils, and Anna Hoefges.

The research appears frequently in venues such as Regular and Young Investigator Award Abstracts, Journal for ImmunoTherapy of Cancer, Cancer Research, Journal of Clinical Oncology, and bioRxiv (Cold Spring Harbor Laboratory).

Best Publications

  • Graft-versus-leukemia reactions after bone marrow transplantation

    MM Horowitz;RP Gale;PM Sondel;JM Goldman

  • Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

    Alice L. Yu;Andrew L. Gilman;M. Fevzi Ozkaynak;Wendy B. London

  • Differential function of major histocompatibility complex antigens in T-lymphocyte activation.

    Fritz H. Bach;Marilyn L. Bach;Paul M. Sondel

  • Results of Allogeneic Bone Marrow Transplants for Leukemia Using Donors Other Than HLA-Identical Siblings

    R Szydlo;J M Goldman;J P Klein;R P Gale

  • NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy.

    Wei Wang;Amy K. Erbe;Jacquelyn A. Hank;Zachary S. Morris

  • Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors.

    Alexander L. Rakhmilevich;Joel Turner;Maura J. Ford;Dennis McCabe

  • Cell Mediated Immunity: Separation of Cells Involved in Recognitive and Destructive Phases

    Fritz H. Bach;Miriam Segall;Karen Stouber Zier;Paul M. Sondel

  • Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

    Suzanne S. Shusterman;Wendy B. London;Stephen D. Gillies;Jacquelyn A. Hank

  • Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

    Rajen Mody;Arlene Naranjo;Collin J Van Ryn;Alice L. Yu;Alice L. Yu

  • Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion.

    R. C. Ash;M. M. Horowitz;R. P. Gale;D. W. van Bekkum

  • HL-A LD (lymphocyte defined) typing: a rapid assay with primed lymphocytes.

    Michael J. Sheehy;Paul M. Sondel;Marilyn L. Bach;Rudolf Wank

  • Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta.

    A C Ochoa;G Gromo;B J Alter;P M Sondel

  • A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group.

    Jami D. Frost;Jami D. Frost;Jacquelyn A. Hank;Gregory H. Reaman;Sharon Frierdich

  • A First-in-Human Phase I Study of Subcutaneous Outpatient Recombinant Human IL15 (rhIL15) in Adults with Advanced Solid Tumors

    Jeffrey S. Miller;Chihiro Morishima;Douglas G. McNeel;Manish R. Patel

  • Phase I Study of ch14.18 With Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-2 in Children With Neuroblastoma After Autologous Bone Marrow Transplantation or Stem-Cell Rescue: A Report From the Children's Oncology Group

    Andrew L. Gilman;M. Fevzi Ozkaynak;Katherine K. Matthay;Mark Krailo

  • Gamma/delta T cell clones and natural killer cell clones mediate distinct patterns of non-major histocompatibility complex-restricted cytolysis.

    P. Fisch;M. Malkovsky;E. Braakman;E. Sturm

  • Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity

    Kory L. Alderson;Paul M. Sondel

  • Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.

    Jacquelyn A. Hank;Randy R. Robinson;Jean Surfus;Barbara M. Mueller

  • Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?

    O Ringden;MM Horowitz;P Sondel;RP Gale

  • BIOLOGIC RESPONSE MODIFIER-INDUCED INDOLEAMINE 2,3-DIOXYGENASE ACTIVITY IN HUMAN PERIPHERAL BLOOD MONONUCLEAR CELL CULTURES'

    Joseph M. Carlin;Ernest C. Borden;Paul M. Sondel;Gerald I. Byrne

  • A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14.18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory Neuroblastoma.

    Sara M. Federico;Sara M. Federico;M. Beth McCarville;Barry L. Shulkin;Paul M. Sondel

  • Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.

    Ilia N. Buhtoiarov;Paul M. Sondel;Jon M. Wigginton;Tatiana N. Buhtoiarova

  • Immunocytokines for cancer treatment: past, present and future

    Dario Neri;Paul M Sondel

  • In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments

    Zachary S. Morris;Emily I. Guy;David M. Francis;Monica M. Gressett

  • Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.

    Fariba Navid;Paul M. Sondel;Raymond Barfield;Barry L. Shulkin

  • Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.

    Zane C. Neal;Jeannie C. Yang;Alexander L. Rakhmilevich;Ilia N. Buhtoiarov

Frequent Co-Authors

Jacquelyn A. Hank
Jacquelyn A. Hank University of Wisconsin–Madison
Stephen D. Gillies
Stephen D. Gillies MSD (United States)
Ralph A. Reisfeld
Ralph A. Reisfeld Scripps Research Institute
Alice L. Yu
Alice L. Yu University of California, San Diego
John M. Maris
John M. Maris Children's Hospital of Philadelphia
Wendy B. London
Wendy B. London Harvard University
Robert C. Seeger
Robert C. Seeger Children's Hospital of Los Angeles
Katherine K. Matthay
Katherine K. Matthay University of California, San Francisco
Susan L. Cohn
Susan L. Cohn University of Chicago
Mary M. Horowitz
Mary M. Horowitz Medical College of Wisconsin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those studying Immunology in the USA, exploring related online degrees can open doors to diverse career paths in healthcare. Many immunology students transition into nursing and advanced practice roles, where their scientific background is valuable. For example, accelerated programs tailored to healthcare professionals can expedite the journey toward becoming a Nurse Practitioner (NP). Discover some of the best options by reviewing the accelerated NP program pathways available online.

Transitioning within nursing roles is common, especially moving from a Family Nurse Practitioner (FNP) to an Acute Care Nurse Practitioner (ACNP). This shift allows immunology graduates to apply their specialized knowledge in acute care settings. Guidance on making this change can be found in resources discussing FNP to ACNP transitions.

For non-nurses interested in entering healthcare, comprehensive online nursing programs for non nurses offer foundational training that complements immunology expertise. Such programs can be a strategic starting point for a clinical career.

Finally, understanding the financial prospects related to advanced degrees is crucial. For example, the DNP salary information provides insight into return on investment for Doctor of Nursing Practice graduates, helping students make informed decisions about their educational and professional future.

Best Scientists Citing Paul M. Sondel

Trending Scientists

Recently Published Articles